Oncodea develops an AI-powered technology that analyzes cancer molecular fingerprint data using machine learning to predict outcomes for unknown samples. This platform enables faster cancer detection and supports routine monitoring of treatment progress for patients and health-conscious individuals. The core value is providing comprehensive and accessible cancer detection solutions.
Funding
$280K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
WTFounders
Product
Problem
Current methods for early cancer detection and monitoring are often expensive and inaccessible, hindering proactive health management and timely treatment adjustments. The lack of affordable and comprehensive solutions limits the ability of individuals and patients to maintain cancer-free health and track treatment progress effectively.
Solution
Oncodea offers an AI-powered platform that leverages cancer molecular fingerprint data and machine learning to facilitate early cancer detection and monitoring. The platform analyzes unknown cancer samples to predict outcomes, enabling faster detection and improved patient outcomes. By providing a cost-effective solution, Oncodea aims to make comprehensive cancer detection accessible to a broader population, supporting proactive health management and informed treatment decisions.
Target Audience
The primary users are individuals seeking to maintain cancer-free health and cancer patients who need to routinely monitor their treatment progress.
Features
- AI-powered analysis of cancer molecular fingerprint data
- Machine learning algorithms for predicting cancer sample outcomes
- Platform designed for early cancer detection
- Monitoring capabilities for tracking treatment progress
- Cost-effective solution for individuals and patients